BioCentury
ARTICLE | Finance

Gut reaction

Synlogic using $29.4M series A to fine-tune bacterial drug delivery

July 28, 2014 7:00 AM UTC

Synlogic Inc. is using its $29.4 million series A round to develop engineered microbes that could enable more fine-tuned delivery of therapeutic proteins than other bacterial delivery platforms, as well as have a unique ability to process toxins.

Last week, the company raised an undisclosed amount in the tranched round co-led by existing investor Atlas Venture and new investor New Enterprise Associates...